心力衰竭中DBNL的分子机制:从巨细胞免疫代谢到治疗影响
Binbin Cao1, Zehao Zhao2, Cui Li1
1Department of Cardiology, The First Affiliated Hospital of Ningbo University.
Journal of visualized experiments : JoVE
|January 19, 2026
概括
这项研究确定了德雷布林类 (DBNL) 基因是心力衰竭进展的关键基因,主要是在心脏巨细胞中. 皮里尼西克酸显示了调节DBNL的潜力,提供了新的治疗点.
科学领域:
- 心血管研究研究心血管研究
- 基因组学和生物信息学
- 免疫学 免疫学 免疫学
背景情况:
- 心力衰竭 (HF) 是一个重大的全球健康挑战,有效治疗方法有限.
- 了解高血压的遗传和分子基础对于开发新的治疗策略至关重要.
研究的目的:
- 通过综合的多组学方法,识别潜在的心力衰竭生物标志物和治疗点.
- 阐明德雷布林类 (DBNL) 在HF病原和巨细胞功能中的作用.
主要方法:
- 组合的孟德尔随机化 (MR) 与单细胞RNA测序 (scRNA-seq).
- 分析了GWAS,eQTL,mQTL和pQTL的数据.
- 研究了心脏巨细胞中的DBNL表达和调节,包括伪性时间分析.
- 利用分子对接和动力学模拟来识别潜在的药物调节剂.
主要成果:
- DBNL被确定为与HF风险相关的关键基因,并且在病理条件下在心脏巨细胞中升调.
- 巨细胞中的DBNL表达与免疫代谢和益纤维素通路 (IL-6/JAK/STAT3,PI3K/AKT/mTOR,TGF-β) 相相关.
- 皮里尼西克酸 (WY-14643) 被计算预测为DBNL的潜在调节者.
结论:
- DBNL在心力衰竭的进展中起着重要作用,特别是通过其对巨细胞分化和免疫代谢的影响.
- DBNL代表了心力衰竭的潜在治疗标.
- 计算预测表明皮里尼西克酸是DBNL向治疗的候选者,需要进一步的实验验证.
相关概念视频
01:29Heart Failure II: Pathophysiology
768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
01:22Heart Failure VI: Adjunct Therapies
273
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
01:22Heart Failure Drugs: Diuretics
821
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
01:30Heart Failure V: Medical Management
225
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225